ישראל -
עברית -
Ministry of Health
נורווסק 5 מג טבליות
pfizer pfe pharmaceuticals israel ltd - amlodipine as besylate - טבליה - amlodipine as besylate 5 mg - amlodipine - amlodipine - mild to moderate hypertension. vasospastic angina ( prinzmetal's or variant angina). chronic stable angina.
ישראל -
עברית -
Ministry of Health
סוטנט 12.5 מג
pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 12.5 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.
ישראל -
עברית -
Ministry of Health
סוטנט 25 מג
pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 25 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.
ישראל -
עברית -
Ministry of Health
סוטנט 50 מג
pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 50 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.
ישראל -
עברית -
Ministry of Health
קסאלקורי 200 מג
pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.
ישראל -
עברית -
Ministry of Health
קסאלקורי 200 מג
pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.
ישראל -
עברית -
Ministry of Health
קסאלקורי 250 מג
pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 250 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.
ישראל -
עברית -
Ministry of Health
קסאלקורי 250 מג
pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 250 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.
ישראל -
עברית -
Ministry of Health
אינלייטה 1 מג
pfizer pharmaceuticals israel ltd - axitinib - טבליות מצופות פילם - axitinib 1 mg - axitinib - axitinib - for the treatment of advanced renal cell carcinoma (rcc) after failure of one prior systemic therapy.
ישראל -
עברית -
Ministry of Health
אינלייטה 5 מג
pfizer pharmaceuticals israel ltd - axitinib - טבליות מצופות פילם - axitinib 5 mg - axitinib - axitinib - for the treatment of advanced renal cell carcinoma (rcc) after failure of one prior systemic therapy.